The Lung Transplant Awareness Day inaugural sponsor Lung Bioengineering, a subsidiary of United Therapeutics, has received FDA approval for the first device for centralized ex vivo lung perfusion of donor lungs.
Ex Vivo Lung Perfusion (EVLP) technology allows donor lungs to be sustained and evaluated outside the body prior to a transplant.
“Today’s approval is a big step forward in reducing the large number of donor lungs—over 80%—that are unfortunately left behind instead of being transplanted,” Martine Rothblatt, Ph.D., chairperson and chief executive officer of United Therapeutics, said in the announcement.”
The Lung Transplant Foundation is proud to share this update from our inaugural Lung Transplant Awareness Day sponsor as they continue to innovate in patient care.
To read the complete medical specifications and details of the FDA approval, view the full article on Medical Economics:
Creating a world where all lung transplant patients live long, healthy lives.
1249 Kildaire Farm Road, Suite 323
Cary, NC 27511
Disclaimer: This website does not provide medical advice. The information, including but not limited to text, graphics, images, and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment before undertaking any new health care regimen. Never disregard any professional medical advice or delay in seeking care because of something you have read on this website.
